Literature DB >> 23200789

Identification of blocker binding site in mouse TRESK by molecular modeling and mutational studies.

Songmi Kim1, Yuno Lee, Hyun-Min Tak, Hye-Jin Park, Young-Sik Sohn, Swan Hwang, Jaehee Han, Dawon Kang, Keun Woo Lee.   

Abstract

TWIK (tandem-pore domain weak inward rectifying K(+))-related spinal cord K(+) channel, TRESK, a member of the tandem-pore domain K(+) channel family, is the most recently cloned K(2P) channel. TRESK is highly expressed in dorsal root ganglion neuron, a pain sensing neuron, which is a target for analgesics. In this study, a reliable 3D structure for transmembrane (TM) region of mouse TRESK (mTRESK) was constructed, and then the reasonable blocker binding mode of the protein was investigated. The 3D structure of the mTRESK built by homology modeling method was validated with recommend value of stereochemical quality. Based on the validated structure, K(+) channel blocker-bound conformation was obtained by molecular docking and 5ns MD simulation with DPPC lipid bilayer. Our docking study provides the plausible binding mode of known blockers with key interacting residues, especially, F156 and F364. Finally, these modeling results were verified by experimental study with mutation from phenylalanine to alanine (F156A, F364A and F156A/F364A) at the TM2 and TM4. This is the first modeling study for TRESK that can provide structural information of the protein including ligand binding information. These results can be useful in structure based drug design for finding new blockers of the TRESK as potential therapeutic target of pain treatment.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23200789     DOI: 10.1016/j.bbamem.2012.11.021

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

Review 1.  Properties, regulation, pharmacology, and functions of the K₂p channel, TRESK.

Authors:  Péter Enyedi; Gábor Czirják
Journal:  Pflugers Arch       Date:  2014-11-05       Impact factor: 3.657

Review 2.  Two-pore domain potassium channels: potential therapeutic targets for the treatment of pain.

Authors:  Alistair Mathie; Emma L Veale
Journal:  Pflugers Arch       Date:  2014-11-26       Impact factor: 3.657

3.  Functional analysis of a migraine-associated TRESK K+ channel mutation.

Authors:  Ping Liu; Zheman Xiao; Fei Ren; Zhaohua Guo; Ziwei Chen; Hucheng Zhao; Yu-Qing Cao
Journal:  J Neurosci       Date:  2013-07-31       Impact factor: 6.167

4.  Selective and state-dependent activation of TRESK (K2P 18.1) background potassium channel by cloxyquin.

Authors:  Miklós Lengyel; Alice Dobolyi; Gábor Czirják; Péter Enyedi
Journal:  Br J Pharmacol       Date:  2017-05-18       Impact factor: 8.739

5.  Identification of novel small molecule modulators of K2P18.1 two-pore potassium channel.

Authors:  J Kyle Bruner; Beiyan Zou; Hongkang Zhang; Yixin Zhang; Katharina Schmidt; Min Li
Journal:  Eur J Pharmacol       Date:  2014-06-24       Impact factor: 4.432

6.  Aristolochic acid, a plant extract used in the treatment of pain and linked to Balkan endemic nephropathy, is a regulator of K2P channels.

Authors:  Emma L Veale; Alistair Mathie
Journal:  Br J Pharmacol       Date:  2016-04-05       Impact factor: 8.739

7.  Pharmacologically reversible, loss of function mutations in the TM2 and TM4 inner pore helices of TREK-1 K2P channels.

Authors:  Ehab Al-Moubarak; Emma L Veale; Alistair Mathie
Journal:  Sci Rep       Date:  2019-08-27       Impact factor: 4.379

8.  Block of TREK and TRESK K2P channels by lamotrigine and two derivatives sipatrigine and CEN-092.

Authors:  Yvonne Walsh; Michael Leach; Emma L Veale; Alistair Mathie
Journal:  Biochem Biophys Rep       Date:  2021-05-19

9.  Over-expression of TRESK K(+) channels reduces the excitability of trigeminal ganglion nociceptors.

Authors:  Zhaohua Guo; Yu-Qing Cao
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.